Calidi Biotherapeutics (CLDI) CFO Jackson received 300,000 Stock Options (right to buy)

Insider transactions reported

Andrew C. Jackson (Chief Financial Officer at Calidi Biotherapeutics Inc., CLDI) reported that they received 300,000 Stock Options (right to buy) on Jun 17, 2024.

Reporting person

Jackson Andrew C.

Role

Chief Financial Officer

Options and other derivatives

Holdings before and after

• Stock Options (right to buy): 0 to 300,000 direct

Footnotes from the filing

1. 1. Pursuant to the Issuer's 2023 Equity Incentive Plan (the 2023 Plan ), on June 17, 2024 (the Grant Date ), the Reporting Person was granted 300,000 incentive stock options (the Options ) at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 10/30/2023, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ